Kazia Therapeutics (ADR) (KZIA)
Develops paxalisib and licensed oncology programs for treatment-resistant cancers.
$10.10
vs last close−0.82 (−7.55%)
Something off on this page? Send us feedback.
EPSReportedEstimate
Mar '24Sep '24Nov '24Feb '25Jun '25Nov '25Mar '26Sep '26
Reported−$12.53−$0.30−$20.81−$20.80−$3.81−$0.43−$0.58−$0.60
Estimate—−$3.00−$15.00−$15.00−$10.76−$0.01−$0.01−$0.61
Surprise—+90.0%−38.7%−38.7%+64.6%−6,529.9%−8,183.1%+0.9%
RevenueReportedEstimate
Mar '24Sep '24Nov '24Feb '25Jun '25Nov '25Mar '26Sep '26
Reported$3$100.0K$1.7M$1.7M$13.8K$10.5K$180.6K$183.4K
Estimate—$100.0K$100.0K$100.0K$11.1K$10.5K—$488.9K
Surprise—0.0%+1,554.2%+1,554.2%+24.8%+0.3%—−62.5%
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Mar 2027 | −$0.45 | — | — |
| Sep 2026 | −$0.61 | −$0.60 | +0.9% |
| Mar 2026 | −$0.01 | −$0.58 | −8,183.1% |
| Nov 2025 | −$0.01 | −$0.43 | −6,529.9% |
| Jun 2025 | −$10.76 | −$3.81 | +64.6% |
| Nov 2024 | |||
| Feb 2025 | |||
| Sep 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jan 2022 | |||
| Feb 2022 | |||
| Sep 2021 | |||
| Feb 2021 | |||
| Dec 2020 | |||
| Aug 2020 | |||
| Jun 2020 | |||
| Feb 2020 | |||
| Dec 2019 | |||
| Jun 2019 | |||
| Dec 2018 | |||
| Jun 2018 | |||
| Dec 2017 | |||
| Aug 2017 | |||
| Feb 2017 | |||
| Aug 2016 | |||
| Feb 2016 | |||
| Aug 2015 | |||
| Feb 2015 | |||
| Oct 2014 | |||
| Feb 2014 | |||
| Jun 2013 | |||
| Dec 2012 | |||
| Jun 2012 | |||
| Dec 2011 | |||
| Jun 2011 | |||
| Dec 2010 | |||
| Jun 2010 | |||
| Dec 2009 | |||
| Jun 2009 | |||
| Dec 2008 | |||
| Jun 2008 | |||
| Dec 2007 | |||
| Jun 2007 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Mar 2, 2027 | −$0.45 | — | — | — | — | — | — |
| Sep 4, 2026 | −$0.61 | −$0.60 | +0.9% | $488.9K | $183.4K | −62.5% | +1.2% |
| Mar 16, 2026 | −$0.01 | −$0.58 | −8,183.1% | — | $180.6K | — | −7.2% |
| Nov 7, 2025 | −$0.01 | −$0.43 | −6,529.9% | $10.5K | $10.5K | +0.3% | −2.3% |
| Jun 10, 2025 | −$10.76 | −$3.81 | +64.6% | $11.1K | $13.8K | +24.8% | +81.4% |
| Nov 19, 2024 | |||||||
| Feb 20, 2025 | |||||||
| Sep 16, 2024 | |||||||
| Mar 27, 2024 | |||||||
| Nov 27, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Oct 6, 2022 | |||||||
| Jan 6, 2022 | |||||||
| Feb 23, 2022 | |||||||
| Sep 30, 2021 | |||||||
| Feb 24, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Aug 26, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Feb 19, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Aug 30, 2017 | |||||||
| Feb 22, 2017 | |||||||
| Aug 30, 2016 | |||||||
| Feb 22, 2016 | |||||||
| Aug 31, 2015 | |||||||
| Feb 28, 2015 | |||||||
| Oct 3, 2014 | |||||||
| Feb 28, 2014 | |||||||
| Jun 30, 2013 | |||||||
| Dec 31, 2012 | |||||||
| Jun 30, 2012 | |||||||
| Dec 31, 2011 | |||||||
| Jun 30, 2011 | |||||||
| Dec 31, 2010 | |||||||
| Jun 30, 2010 | |||||||
| Dec 31, 2009 | |||||||
| Jun 30, 2009 | |||||||
| Dec 31, 2008 | |||||||
| Jun 30, 2008 | |||||||
| Dec 31, 2007 | |||||||
| Jun 30, 2007 |